Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential
Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential
The increase was primarily driven by increased system sales, higher average selling prices, and increased handpiece and other consumable revenue.PROCEPT BioRobotics (NASDAQ:PRCT) stock is trading on Monday after the company released better-than-expected third-quarter earnings.
PROCEPT BioRobotics（納斯達克：PRCT）股票週一交易，公司發佈了好於預期的第三季度收益。
The company reported EPS loss of $(0.40), down from $(0.51) a year ago, beating the consensus loss of $(0.49).
該公司報告的每股收益虧損爲0.40美元，低於一年前的0.51美元，超過了每股虧損0.49美元的共識。
The surgical robotics company reported third-quarter sales of $58.4 million, up 66.3% year-over-year, beating the consensus of $53.18 million.
這家外科機器人公司報告第三季度銷售額爲5840萬美元，同比增長66.3%，超過了5318萬美元的共識。
The increase was primarily driven by increased system sales, higher average selling prices, and increased handpiece and other consumable revenue.
增長主要是由於系統銷售增加，平均銷售價格提高，以及手柄和其他易耗品收入增加。
U.S. handpiece and consumable revenue for the third quarter of 2024 was $29.6 million, an increase of 74% year over year.
2024年第三季度美國手柄和易耗品收入爲2960萬美元，同比增長74%。
William Blair says the update was promising, especially considering management's remarks on the possibility of procedural disruptions due to the sales team being temporarily removed from the field for training on the new Hydros system.
William Blair表示，這一更新令人鼓舞，尤其是考慮到管理層就可能由於銷售團隊暫時撤離現場接受新Hydros系統培訓而可能出現的程序中斷所作的表示。
U.S. system revenue for the third quarter of 2024 was $19.6 million, an increase of 46%.
2024年第三季度美國系統收入爲1960萬美元，同比增長46%。
As of September 30, the install base of robotic systems in the U.S. was 445 systems.
截至2024年9月30日，美國機器人系統的安裝基數爲445台。
Gross margin for the third quarter was 63.2% compared to 53.8% a year ago, primarily due to improved overhead absorption and increased U.S. robotic system average selling prices.
第三季度的毛利率爲63.2%，相比一年前的53.8%，主要是由於改善了製造費用分攤和美國機器人系統平均售價的提高。
Guidance: PROCEPT BioRobotics projects 2024 revenue of $222.5 million—$223 million, up from prior guidance of $217 million and consensus of $217.06 million.
指引：PROCEPt BioRobotics預計2024年營業收入爲22250萬—22300萬美元，高於之前的指引21700萬美元和市場共識的21706萬美元。
The company projects a 2024 gross margin of approximately 61%, up from prior guidance of approximately 59%.
公司預計2024年的毛利率約爲61%，高於之前約59%的指引。
PROCEPT projects a full-year 2024 adjusted EBITDA of ($60.0) million compared to the previous guidance of ($67.5) million.
PROCEPt預計2024全年調整後的EBITDA爲負60.0百萬美元，而之前的指引爲負67.5百萬美元。
William Blair says, "Overall, there is not much to pick at in third-quarter results, which we think reinforces the strong underlying demand for Aquablation."
William Blair表示：「總體來說，第三季度的業績幾乎沒有什麼值得挑剔的地方，這進一步證實了對Aquablation強勁的基礎需求。」
With the company's U.S. market projected to reach only 10% penetration by the end of 2024, alongside strong utilization growth estimated at 7%, a new system launch in Hydros, improving profitability, and potential catalysts in prostate cancer treatment, the analyst remains optimistic about the upside potential.
隨着公司預計美國市場在2024年底時僅達到10%的滲透率，伴隨着強勁的7%的利用率增長，Hydros的新系統推出，盈利能力的提高，以及在前列腺癌治療方面的潛在催化劑，該分析師對上行潛力仍然持樂觀態度。
William Blair reiterates the Outperform rating.
William Blair重申Outperform評級。
Price Action: PRCT stock is up 28.50% at $88.36 at the last check on Monday.
價格走勢：PRCt股票在星期一最後一次檢查時上漲28.50%，報88.36美元。
- Why Is Moderna Stock Trading Higher On Monday?
- 爲什麼現代a股票週一交易更高？
